Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-28
2011-06-28
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024310, C536S024500
Reexamination Certificate
active
07968526
ABSTRACT:
The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 5834279 (1998-11-01), Rubin et al.
patent: 5998383 (1999-12-01), Wright et al.
patent: 6121000 (2000-09-01), Wright et al.
patent: 6593305 (2003-07-01), Wright
patent: 7405205 (2008-07-01), Wright et al.
patent: 2004/0009948 (2004-01-01), Wright et al.
patent: 2007/0274947 (2007-11-01), Young et al.
patent: 2008/0311126 (2008-12-01), Young et al.
patent: 0 383 190 (1990-08-01), None
patent: 2000-517167 (2000-12-01), None
patent: WO 95/02069 (1995-01-01), None
patent: WO 98/00532 (1998-01-01), None
patent: WO 98/05769 (1998-02-01), None
patent: WO 99/02673 (1999-01-01), None
patent: WO 00/47733 (2000-08-01), None
patent: WO 02/085308 (2002-10-01), None
Agrawal, S. and Kandimalla, E.R, “Antisense and/or Immunostimulatory Oligonucleotide Therapeutics,”Curr. Cancer Drug Targets1:197-209, Hybridon, Inc. (2001).
Amara, F.M, et al., “Phorbol Ester Modulation of a Novel Cytoplasmic Protein Binding Activity at the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase R2 mRNA and Role in Message Stability,”J. Biol. Chem. 269:6709-6715, The American Society for Biochemistry and Molecular Biology, Inc. (1994).
Amara, F.M., et al., “Defining a Novel cis Element in the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase Component R2 mRNA: Role in Transforming Growth Factor-β1Induced mRNA Stabilization,”Nucl. Acids Res. 23:1461-1467, Oxford University Press (1995) Barker, R.H., et al., “Inhibition of Pasmodium falciparum Malaria using antisense oligodeoxynucleotides,” Proc. Natl. Acad. Sci. USA 93:514-518, National Academy of Sciences (1996).
Barker, R.H., et al. “Inhibition ofPasmodium falciparumMalaria using antisense oligodeoxynucleotides,”Proc. Natl. Acad. Sci. USA93:514-518, National Academy of Sciences (1996).
Bitonti, A.J., et al., “Regression of Human Breast Tumor Xenografts in Response to (E)-2'-Deoxy-2'-(fluoromethylene) cytidine, an Inhibitor of Ribonucleoside Diphosphate Reductase,”Cancer Res. 54(6):1485-1490, Marion Merrell Dow Research Institute (1994).
Björklund, S., et al., “S-Phase-Specific Expression of Mammalian Ribonucleotide Reductase R1 and R2 Subunit mRNAs,”Biochem. 29:5452-5457, American Chemical Society (1990).
Branch, A., “A Good Antisense Molecule is Hard to Find,”TIBS23:45-50, Elsevier Science Ltd. (1998).
Caras, I.W., et al., “Cloned Mouse Ribonucleotide Reductase Subunit M1 cDNA Reveals Amino Acid Sequence Homology withEscherichia coliand Herpesevirus Ribonucleotide Reductases,”J Biol. Chem. 260:7015-7022, The American Society of Biological Chemists, Inc. (1986).
Chakrabarti, D., et al., “Cloning and Characterization of Sununit Genes of Ribonucleotide Reductase, a cell-cycle-regulated enzyme, fromPlasmodium falciparum,”Proc. Natl. Acad. Sci. USA90:12020-12024, National Academy of Sciences (1993).
Chaudhuri, M.M., et al. “cDNA Sequence of the Small Subunit of the Hamster Ribonucleotide Reductase,”Biochimi. et Biophys. Acta1171:117-121, Elsevier Science Ltd. (1992).
Chen, F.Y., et al., “Defining a novel ribonucleotide reductase rl mRNA cis element that binds to an unique cytoplasmic trans-acting protein,”Nucl. Acids Res. 22:4796-4797, Oxford University Press (1994).
Chen, F.Y., et al., “Mammalian ribonucleotide Reductase R1 mRNA stability under Normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region,”EMBO J. 12:3977-3986, Oxford University Press (1993).
Chitambar, C.R. and Wereley, J.P., “Effect of Hydroxyurea on Cellular Iron Metabolism in Human Leukemic CCRF-CEM Cells: Changes in Iron Uptake and the Regulation of Transferrin Receptor and Ferritin Gene Expression following Inhibition of DNA Synthesis,”Cancer Res. 55:4361-4366, American Association for Cancer Research (1995).
Chiu, C.S.M., et al., “Inhibition of mammalian ribonucleotide reductase by cisdiamminedichloroplatinum(II),”Biochem. and Cell Biol. 70:1332-1338, NRC Research Press (1992).
Cory, J.G., et al., “Structural Aspects of N-Hydroxy-N'-Aminoguanidine Derivatives as Inhibitors of L1210 Cell Growth and Ribonucleotide Reductase Activity,”Advan. Enzyme Regul. 33:129-140, Pergamon Press Ltd. (1993).
Crooke, S.T. ed., “Chapter 1. Basic Principles of Antisense Therapeutics,” in:Antisense Research and Application, Springer-Verlag, Berlin, DE, pp. 1-50 (1998).
Davis, R., et al., “Purification, Characterization, and Localization of Subunit Interaction Area of Recombinant Mouse Ribonucleotide Reductase R1 Subunit,”J. Biol. Chem. 269:23171-23176, The American Society for Biochemistry and Molecular Biology, Inc. (1994).
Fabianowska-Majewska, K., et al., “2-Chloro-2'-Deoxyadenosine (2CdA)—Biochemical Aspects of Antileukemic Efficacy,”Acta Pol. Pharm.-Drug Res. 53:231239, Polish Pharm. Society (1996).
Fan, H., et al., “Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential,”Proc. Natl. Acad. Sci. USA93:14036-14040, National Academy of Sciences (1996).
Fan, H., et al., “A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated Stable Expression of R2 cDNA,”FEBS Letters382:145-148, Elsevier Science Ltd. (1996).
Fan, H., et al., “The R1 component of mammalian ribonucleotide reductase has malignancy-supressing activity as demonstrated by gene transfer experiments,”Proc. Natl. Acad. Sci. USA94:13181-13186, National Academy of Sciences (1997).
Gandhi, V., et al., “Chlorodeoxyadenosine and Arabinosylcyosine in Patients with Acute Myelogenous Leukemia: Pharmacokinetic, Pharmacodynamic, and Molecular Interactions,”Blood87:256-264, American Society of Hematology (1996).
Giacca, M., et al., “Synergistic Antiviral Action of Ribonucleotide Reductase Inhibitors and 3'-azido-3'-deoxythymidine on HIV Type 1 Infection in Vitro,”Aids Res. Human Retroviruses12:677-682, Mary Ann Liebert, Inc. (1996).
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science278:1041-1042, American Association for Advancement of Science (1997).
Huang, a., et al., “Ribonucleotide Reductase R2 Gene Expression and Changes in Drug Sensitivity and Genome Stability,”Cancer Res. 57:4876-4881, American Association for Cancer Research (1997).
Hurta, R.A.R. and Wright, J.A., “Alterations in the Cyclic AMP Signal Transduction Pathway Regulating Ribonucleotide Reductase Gene Expression in Malignant H-ras Transformed Cell Lines,”J. Cell. Physiol. 158:187-197, Wiley-Liss. Inc. (1994).
Hurta, R.A.R., et al., “Early Induction of Ribonucleotide Reductase Gene Expression by Transforming Growth Factor β1in Malignant H-ras Transformed Cell Lines,”J. Biol. Chem. 266:24097-24100, The American Society for Biochemistry and Molecular Biology, Inc. (1991).
Jensen, R.A., et al., “Identification of genes expressed in premalignant breast disease by microscopy-directed cloning,”Proc. Natl. Acad. Sci. USA91:9257-9261, National Academy of Sciences (1994).
Lee, Y., et al., “GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity Against a Variety of Tumors,”Cancer Res. 63:2802-2811, American Association for Cancer Research (Jun. 2003).
Lepoivre, M., et al., “Alterations of Ribonucloetide Reductase Activity Following Induction of the Nitrite-generating Pathway in Adenocarcinoma Cells,”Bi
Wright Jim A.
Young Aiping H.
Bowman Amy
Lorus Therapeutics Inc.
Sterne Kessler Goldstein & Fox PLLC
LandOfFree
Antisense oligonucleotides directed to ribonucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides directed to ribonucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides directed to ribonucleotide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2622428